SAL007 is expected to provide a new choice for the treatment of chronic heart failure, and bring new hope to the extensive patients with chronic heart failure.
Recently, CA Roam Holdings, an affiliated company of Carlyle Asia Phase V Fund under The Carlyle Group, a global investment company, invested USD 260 million to purchase about 5% of the total share capital of Salubris.
In August 2020, Salubris received the Notice of Approval of Clinical Trials from National Medical Products Administration, and initiated human clinical trials.
Recently, Alain Medical (Beijing) Co., Ltd. (hereinafter referred to as "Alain Medical ") received the Medical Device Registration Certificate approved and issued by National Medical Products Administration, and the MAURORA ? Rapamycin drug-eluting v
Salubris Biotherapeutics, Inc., (hereinafter referred to as "SalubrisBio"), as a wholly owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd., submitted a clinical application for SAL007 to FDA on January 23, 2020, and was successfully appro
On December 25, 2019, Salubris formally signed an agreement with Japan's JAPAN TOBACCO INC. (hereinafter referred to as "JT") at its headquarters in Shenzhen
